473 related articles for article (PubMed ID: 30867573)
21. Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy.
Sebbag E; Psimaras D; Baloglu S; Bourgmayer A; Moinard-Butot F; Barthélémy P; Tranchant C; Honnorat J; Bender L
J Neuroimmune Pharmacol; 2022 Dec; 17(3-4):377-379. PubMed ID: 34687000
[TBL] [Abstract][Full Text] [Related]
22. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
Vilariño N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
24. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
25. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
[TBL] [Abstract][Full Text] [Related]
26. A review of the imaging manifestations of immune check point inhibitor toxicities.
Thomas R; Sebastian B; George T; Majeed NF; Akinola T; Laferriere SL; Braschi-Amirfarzan M
Clin Imaging; 2020 Aug; 64():70-79. PubMed ID: 32334270
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week.
Ball S; Ghosh RK; Wongsaengsak S; Bandyopadhyay D; Ghosh GC; Aronow WS; Fonarow GC; Lenihan DJ; Bhatt DL
J Am Coll Cardiol; 2019 Oct; 74(13):1714-1727. PubMed ID: 31558256
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.
Hansen ED; Wang X; Case AA; Puzanov I; Smith T
J Pain Symptom Manage; 2018 Sep; 56(3):460-472. PubMed ID: 29792979
[TBL] [Abstract][Full Text] [Related]
29. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
30. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
31. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
[TBL] [Abstract][Full Text] [Related]
32. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
[TBL] [Abstract][Full Text] [Related]
33. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
Valencia-Sanchez C; Zekeridou A
Front Neurol; 2021; 12():642800. PubMed ID: 33897597
[TBL] [Abstract][Full Text] [Related]
34. Neurological complications of cancer immunotherapy.
Roth P; Winklhofer S; Müller AMS; Dummer R; Mair MJ; Gramatzki D; Le Rhun E; Manz MG; Weller M; Preusser M
Cancer Treat Rev; 2021 Jun; 97():102189. PubMed ID: 33872978
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.
Blaes F
Expert Rev Neurother; 2021 Jun; 21(6):675-686. PubMed ID: 33960258
[No Abstract] [Full Text] [Related]
36. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
37. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
38. Ovarian Teratoma-Related Paraneoplastic Neurological Syndromes.
Lin J; Wang M; Wang J; Li J
Front Oncol; 2022; 12():892539. PubMed ID: 35651803
[TBL] [Abstract][Full Text] [Related]
39. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
40. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
